BioAffinity Technologies IR Responder (@BIAF_IRresponse) header
BioAffinity Technologies IR Responder (@BIAF_IRresponse) profile picture

Welcome to the official X profile of bioAffinity Technologies, Inc. (NASDAQ: BIAF). See disclaimer: https://teapaw.org/t.co/kqEnAbfpJ4

Joined November 2026
$BIAF October marked our highest monthly CyPath® Lung testing volume representing a 29% increase compared with October 2025. Both established and newly ordering physicians are providing a new measure of utilization following the close of Q3.
1
2
For our business, expanding adoption means reaching new physicians while increasing use of our test among those already ordering CyPath Lung. October’s record reflects activity across both groups.
1
2
We’re supporting these efforts through increased marketing, an expanded sales team, direct physician engagement and our relationships with patient advocacy organizations to strengthen our connections within the lung cancer community.
2
$BIAF At bioAffinity Technologies, we’re building our business around a clear clinical need: helping physicians determine next steps in care through noninvasive testing for patients at risk for lung cancer.
1
1
11
Our priorities are expanding physician adoption, building clinical evidence and supporting the commercial growth of CyPath Lung.
1
1
3
This official Investor Relations channel is here to keep you informed about our business, science and progress. We want to hear your questions and perspectives. Your voice matters.
1
3